Open AccessIntravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.
Author(s) -
Jeffrey H. Kordower,
Vincent Charles,
Robert Bayer,
Raymond T. Bartus,
Scott D. Putney,
Lee Walus,
Phillip M. Friden
Publication year - 1994
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.91.19.9077
Subject(s) - quinolinic acid , nerve growth factor , choline acetyltransferase , neurotrophic factors , conjugate , endocrinology , medicine , systemic administration , cholinergic neuron , transferrin , antibody , neurotrophin , huntington's disease , receptor , pharmacology , cholinergic , biology , immunology , disease , biochemistry , in vivo , tryptophan , mathematical analysis , amino acid , microbiology and biotechnology , mathematics
Intrastriatal injections of quinolinic acid induce a pattern of neuronal degeneration similar to that seen in Huntington disease. In the present study, nerve growth factor (NGF) crossed the blood-brain barrier in a dose-dependent fashion following intravenous infusion when conjugated to an antibody directed against the transferrin receptor (OX-26). Intravenous injections of the OX-26-NGF conjugate selectively prevented the loss of striatal choline acetyltransferase-immunoreactive neurons which normally occurs following quinolinic acid administration relative to control rats receiving vehicle or a nonconjugated mixture of OX-26 and NGF. These data demonstrate that a neurotrophic factor-antibody conjugate can prevent the degeneration of central NGF-responsive neurons following systemic administration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom